Thermon Reports Fiscal 2017 Results
May 24, 2017 12:07 pm UTC| Business
SAN MARCOS, Texas, May 24, 2017 -- Thermon Group Holdings, Inc. (NYSE:THR) (the "Company," "Thermon," "we" or "our") today announced consolidated financial results for the fourth quarter ("Q4 2017") and the fiscal year...
Thermon Reports Fiscal 2017 Results
May 24, 2017 12:07 pm UTC| Business
SAN MARCOS, Texas, May 24, 2017 -- Thermon Group Holdings, Inc. (NYSE:THR) (the "Company," "Thermon," "we" or "our") today announced consolidated financial results for the fourth quarter ("Q4 2017") and the fiscal year...
Thermon Reports Fiscal 2017 Results
May 24, 2017 12:07 pm UTC| Business
SAN MARCOS, Texas, May 24, 2017 -- Thermon Group Holdings, Inc. (NYSE:THR) (the "Company," "Thermon," "we" or "our") today announced consolidated financial results for the fourth quarter ("Q4 2017") and the fiscal year...
Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study
May 24, 2017 12:06 pm UTC| Business
PLYMOUTH MEETING, Pa., May 24, 2017 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and...
Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study
May 24, 2017 12:06 pm UTC| Business
PLYMOUTH MEETING, Pa., May 24, 2017 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and...
Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study
May 24, 2017 12:06 pm UTC| Business
PLYMOUTH MEETING, Pa., May 24, 2017 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and...
Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study
May 24, 2017 12:06 pm UTC| Business
PLYMOUTH MEETING, Pa., May 24, 2017 -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and...